All Essential Benefits/Effects/Facts & Information
Harpagophytum Procumbens (commonly called Devil's Claw) is a tuber vegetable that is used for combatting lower back pain as well as arthritis (both osteoarthritis and rheumatoid arthritis). It appears to have efficacy at this, and may take a few months to reach maximal efficacy (so it would be unlikely something like Aspirin, which acts fairly fast).
Human trials have been conducted on Devil's Claw and arthritis, and although there appear to be a large amount of trials conducted on it many are not sourced online or in Medline (instead mentioned vicariously through systemic reviews and meta-analysis' on the subject) and the power of these trials are limited, due to sample sizes and lack of control for the most part. That being said, at least two well controlled trials note that the efficacy of Devil's Claw is greater than placebo with one saying it is of similar potency to Vioxx (Rofecoxib, a COX2 inhibitor and antiinflammatory).
Not too much research into other effects of Devil's Claw, although one study suggests it has remarkable anticholesterase inhibitory potential with the potency on butrylcholinesterase (a cholinesterase enzyme found in the blood and liver) being greater than Galantamine.
There appears to be much discussion on safety of Devil's Claw, which may have stemmed from traditional users of Devil's Claw warning about excessive usage. In short term trials it appears to be well tolerated, with a lack of long term evidence. It is definitely possible that it may induce uterine contractions when taken orally, and due to this it should not be used by pregnant women.
Follow this Page for updates
Devil's Claw (Harpagophytum procumbens of the family Pedaliaceae) is an African herb that can be found in Namibia, Botswana, South Africa, Angola, Zambia, and Zimbabwe; traditional usage of Devil's Claw is as an analgesic, for fevers and allergies, appetite stimulation, wounds and skin rashes, dyspepsia, liver and kidney disorders, as diuretic and sedative, and to treat degenerative disorders of the musculoskeletal system The dried tubers tend to be the active part of the plant used (specifically the secondary tubers, those that branch off the main stems), despite the name of Devil's Claw being drawn from the fruits; the fruits of Harpagophytum procumbens tend to have two straight thorns and numerous characteristically long protrusions with sharp, grapple-like hooks. Other names for this plant, Grapple plant and Duiwelsklou, also refer to these claw-like protrusions and the species name (Harpagophytum) is derived from Harpago, the Greek term for the grappling hook. Some other names include Wood Spider.
The herb Harpagophytum zeyheri is also sometimes referred to as Devil's Claw, although it is lower in bioactives and is commonly seen as an adulterant. The presence of the molecule known as 6-acetylacteoside can be used to detect the species, as it is present in Procumbens but absent in Zeyheri as can the ratio of 8-O-p-coumaroylharpagide to the sum of Harpagoside as it is below 10% in Procumbens yet higher than 31% in Zeyheri.
Harpagophytum procumbens can be further divided into two subspecies; H. procumbens subsp. procumbens or H. procumbens subsp. transvaalense.
Devil's Claw is a name given to the plant Harpagophytum procumbens due to the appearance of claws on the fruits; the storage form of the plant, the tubers, are used medicinally while the name is due to the fruits which are not used medicinally
Devil's Claw contains:
The simple Irioid Glycosides known as Harpagide and Procumbide
Derivatives of Harpagide including Harpagoside (also known as 8-cinnamoylharpagide), 8-cinnamoylmyoporoside, 8-O-feruloylharpagide (1% of commercial extracts, 0.25% dry plant weight), and (same glycoside) as well as Harprocumbide A and 6-O-alpha-D-galactopyranosylharpagoside (different glycosides) and Pagide
8-O-(p-coumaroyl)-harpagide and 8-O-(cis-p-coumaroyl)-harpagide, built off Harpagide and both referred to by the acronym of 8-PCHG
Derivatives of Procumbide including harprocumbide B and 6"-O-(p-coumaroyl)-procumbide
Pagoside and Methoxypagoside
Pentacyclic saponins Nigaichigoside F1 and F2, Chebuloside II, and Harproside
Phenolic/Phenylethanoid Glycosides such as Acteoside (also known as Verbascoside, the main Phenylethanoid Glycoside at up to 15.8% of ethanolic extracts or 2% plant dry weight) and Isoacteoside (5% ethanolic extract), as well as 6-acetylacteoside, 6'-O-acetylacteoside (10% ethanolic extract), 2'-O-Acetylacetoside (2% ethanolic extract) 2,6-diacetylacteoside (3% ethanolic extract), Martynoside, Leucosceptoside A and β-OH-verbascoside
(+)-8,11,13-totaratriene-12,13-diol (built off of a totarane structure)
(+)-8,11,13-abietatrien-12-ol (Ferruginol, built off of an abietane structure) and 13-hydroxytotara-7,9,13-trien-6,12-dione (Maytenoquinone)
Chinane-type tricyclic diterpenoids, which have been noted to form a Diels-Adder product
Cinnamic acid and Caffeic Acid
7α-hydroxysitosterol and 7β-hydroxysitosterol
When looking at Harpagoside, which is commonly seen as the molecule to assess for standardization and a biomarker of the medicinally efficacy of the plant, the secondary tubers appear to have twice as much Harpagoside as the primary tubers; the flowers, fruits, and stems are seemingly absent while leaves have trace amounts. The tubers tend to contain anywhere between 0.5-3% Irioid Glycosides (the class seen as bioactive)
The active ingredient(s) is/are not fully established, but Harpagoside is commonly referred to as the active ingredient since products with Harpagoside are the same products with therapeutic efficacy. Due to this, Harpagoside is a marker of efficacy and is usually standardized to above 1.2% total weight
The phenylethanoid glycosides are most likely contributors to the therapeutic effects, since they are found in high quantities in the ethanolic extracts (commonly used for anti-inflammatory purposes) and have anti-inflammatory effects in isolation
2.1. Enzymatic Interactions
A study assessing interactions of Devil's Claw with P450 noted interactions with CYP3A4 (IC50 values of 124.2-327.6µg/ml) and PXR (EC50 values of 10.21-169.3µg/ml), neither of which were attributable to Harpagoside or Harpagide and the potency deemed of minimal concern for drug-drug interactions.
One study noted that Devil's Claw extracts (commercial blends) was able to inhibit P-Glycoprotein as assessed by an accumulation of Calcein-AM in cells (accumulation of which is indicative of P-gp inhibition) with an EC50 value between 262.4-303.6μg/mL; significantly weaker than the reference drugs Vermapril (5.1μM), Celecoxib (8.3μM), and Nimesulide (20.4μM). This was wholly unrelated to the Harpagoside content, which was inactive.
A phenylethanoid (PE) fraction from Devil's Claw appears to have cholinesterase inhibiting properties (crude extracts ineffective), and may increase acteylcholine levels secondary to this. This study noted that, in vitro, the PE fraction inhibited acetylcholinesterase in a concentration dependent manner from 50-200ug/mL (56.87-73.17% inhibition) and butrylcholinesterase, where the latter had complete inhibition with the cell suspension PE extract (50-200ug/mL; 93.16-100.0%) and nearly complete with the hairy roots PE extract (100-200ug/mL, 86.52-90.66%) and outperformed Galantamine as the active control. Isolated Verbascoside (main phenylethanoid in Devil's Claw) showed dose dependent inhibition on both enzymes, but could not account for the majority of inhibition (reaching 47.94% and 39.19% inhibition at 200ug/mL respectively).
Traditionally, a root powder has been given at doses of 250mg thrice daily to pregnant women to alleviate pain.
When assessing pain reducing effects, 30-300mg of Devil's Claw extract dose dependently reduced pain (as assessed by formalin-induced liking and biting) in mice. The degree of licking/biting was reduced 18.1 and 27.1% in the first phase (100 and 300mg/kg respectively) and 42.5% and 59.0% in the second phase. The pain reducing effects were similar in the second phase to Grape Seed Extract (which was ineffective in the first phase) and more potent than that of Hypericum Perforatum; Devil's Claw appeared to be mediated by opioidergic mechanisms as it was partially abolished by Naxolone.
4Inflammation and Immunology
An ethanolic extract of Devil's Claw in activated monocytes is able to dose-dependently reduce the release of proinflammatory cytokines TNF-α, IL-6, PGE2, and IL-1β with significance at 100mcg/mL or above, and nearly abolishing TNF-α release at 500mcg/mL; the IC50 being thought to be slightly lower than 100mcg/mL. p38 MAPK and JNK were unaffected (and NF-kB, usually a mediator, was uninvolved), but AP-1 binding to the genome was abolished at 100-200mcg/mL in both monocytes and macrophages with similar reductions in cytokines at 500mcg/mL being replicated elsewhere. Harpagoside may be active in this regard as it in isolation has been linked to both inhibition of nitric oxide (NO) and the release of inflammatory cytokines (200uM).
These anti-inflammatory effects have been noted in a whole blood assay where COX-1 and COX-2 were inhibited to roughly similar degrees and nitric oxide release attenuated; the potency correlating with Harpagoside content.
Appears to inhibit AP-1 from influencing the genome, and thus prevent the production of pro-inflammatory cytokines in response to inflammatory stressors. Harpagoside itself may be active, but other constituents appear to contribute
In regards to the Irioid Glycosides, most appear to be either inactive or relatively weak in inhibiting macrophage respiratory burst although 8-O-(p-coumaroyl)-harpagide is moderately effective with an IC50 of 32µM, a mechanism that has been noted elsewhere with Triterpenoids in inhibiting Neutrophil respiratory burst.
Several bioactives appear to lessen the activity of respiratory (oxidative) burst, which may underlie antiinflammatory and antioxidative properties
4.2. Cartilage and Joints
A study in rabbits fed 150mg Devil's Claw extract (14% Harpagoside; said to correlate to 200mg Harpagoside for humans) for six months after unilateral medial meniscectomy and transection of the anterior cruciate ligament (surgery to damage cartilage) noted that control rats had 30% reduction in cartilage thickness in the operated knee relative to control knee; the group fed Devil's Claw had a less difference, but it did not reach statistical significance. A letter to the Editor (of the journal Phytomedicine) discussing this rabbit study noted that Haematoxylin and safranin staining of the joints showed a trend towards increased cartilage regeneration while elastin stainings reached statistical significance, and that mRNA levels of TIMP-2 were increased a variable 2-5 fold higher than control.
One study in rabbits has quantitatively assessed cartilage repair rates with Devil's Claw, and came back negative (a trend to inducing repair, but was not statistically significant)
When looking at rat studies, arthritis induced by injections of M. butyricum had the paw edema significantly reduced by oral administration of 50mg/kg Devil's Claw (50% ethanolic extract) but was less potent than the active control of prednisone at 10mg/kg. This builds off a previous study where 100mg/kg of a 60% ethanolic extract was able to abolish the increase in edema induced by Freund's Adjuvant (research toxin to induce arthritis) and showed dose dependence at 25 and 50mg/kg.
Contrasting that data is one study where 2g/kg Devil's Claw outright failed to exert anti-inflammatory effects in response to M. butyricum or lambda-carrageena induced arthritis. This study does not mention sourcing of the Devil's Claw, and was 11 days in duration (whereas more recent studies in rats are longer in duration).
In rats, it appears to reduce inflammation in models of arthritis. The potency does not appear to exceed that of reference drugs (Prednisone) when tested
Numerous observational studies exist (minimal controls) to suggest benefit to osteoarthritis associated with Devil's Claw, with 8 cited in one meta-analysis but minimal available online. This review as well as a few others note that the evidence is promising but minimal.
For studies available online, one study using the brand name product Doloteffin (2400mg Devil's Claw standardized to 60mg Harpagoside) over 8 weeks noted improvements on symptoms of Osteoarthritis (hip, lower back, and knee) as assessed by WOMAC, Arhus low back pain index, and a modified HAQ; Benefits were apparent in 50-70% of persons, with more benefit being seen in older persons of those with worse disease pathology. Another study conducted over 6 weeks using the same dose of Doloteffin noted that the reduction in pain was comparable to 12.5mg Rofecoxib (COX2 inhibitor), and when patients of this study are given Doloteffin for a year afterwards the pain reduction seems to reach peak efficacy around 30-60 days and then persist at the same magnitude although other sources cite it may take up to 4 months to realize maximal benefits from Devil's Claw.
Surprisingly little evidence available online, but there appears to be a large amount of trials published in German not available via Medline (with one meta-analysis citing up to 10 studies unretrievable via search engines). Devil's Claw appears to be effective for chronic pain, either weaker or comparable to reference drugs (of which comparative trials are minimal)
Traditional usage of Devil's Claw appears to be somewhat limited, with warnings of cancer with overconsumption (definition of what 'cancer'; is to traditional medicine is quite vague) and criticism from tradtional users that modern medicinal usage may be overusing Devil's Claw.
In rats, the LD50 has been said to be above 13.5g/kg bodyweight (with this study mentioning preclinical trials conducted in their lab) with this study also citing that 7.5g/kg of Devil's Claw orally for 21 days failed to significantly alter serum parameters measured. These doses, in human estimated equivalents, are 2.16 and 1.2g/kg bodyweight.
A meta-analysis of human evidence looking at the safety of Devil's Claw notes that in trials of Osteoarthritis that around 10% or less of persons report side-effects, which are of mild severity up to high oral doses (8100mg basic extract). The most common side-effects are gastrointestinal (flatulence and diarrhea) with some reports of headaches and migraines likely related to Devil's Claw intervention. Dyspepsia has also been reported. This meta-analysis also cited a lack of long term evidence.
Some sources state that traditional usage advises against long-term usage, there is inadequate evidence to address this concern currently; short term usage does not appear to be associated with any significant side-effects aside from possible gastrointestinal disturbances
Traditional usage of Devil's Claw involved topical solutions applied to the belly of pregnant women to ease pain and more commonly used postpartum to alleviate pain, yet alternatively high oral doses were said to induce birth or expel placentas. When investigating this claim, high concentrations (200-1000ug/mL) of the extract in isolated uterine muscles can induce contractions in both pregnant and non-pregnant rat uterine strips.
Due to traditional usage for expelling placentas and preliminary evidence saying that Devil's Claw can induce uterine contractions, usage of Devil's Claw should be avoided during pregnancy